| Size | Price | Stock | Qty |
|---|---|---|---|
| 25g |
|
||
| Other Sizes |
| Targets |
Pyridazine does not have a defined pharmacological target of its own, as it is a synthetic building block. However, the pyridazine ring is found in many herbicides like credazine and pyridatol, and in many pharmaceutical drugs like cefozopran, olaparib, and talazoparib. As a diazine, it serves as a core scaffold for the synthesis of various biologically active compounds.
|
|---|---|
| ln Vitro |
An N-bridgehead aromatic heterocycle with two nitrogen atoms, pyrrolo[1,2-b]pyridazine 1 is produced when pyridazine and pyrrole condense.
In vitro, pyridazine is primarily used as a chemical reagent and synthetic intermediate. It is commonly prepared by the reaction of 1,4-dicarbonyls with hydrazines. The compound is mainly used in research and industry as a building block for more complex compounds. As a diazine, it is a common scaffold for the construction of drug-like molecules and agrochemicals. |
| ln Vivo |
In vivo activity data for pyridazine itself are not available, as the compound is not intended for direct in vivo administration. Rather, it is a precursor used in the synthesis of drug candidates and agrochemicals that are subsequently evaluated in vivo. The compound's in vivo relevance is indirect, through the biological activities of the final compounds derived from it, including pharmaceuticals like olaparib and talazoparib.
|
| Enzyme Assay |
For in vitro enzyme/receptor binding studies, pyridazine is not typically evaluated as a test compound itself. Instead, it serves as a reagent for the synthesis of test compounds. The compound's properties include a molecular weight of 80.09 g/mol, a melting point of -8°C, a boiling point of 208°C, a density of 1.103 g/mL, and a flash point of 85°C. The pyridazine ring provides a scaffold for medicinal chemistry.
|
| Cell Assay |
For in vitro cell-based experiments, pyridazine is used as an intermediate in the synthesis of compounds that are tested in cell viability, proliferation, and cytotoxicity assays. The compound itself is not typically evaluated in cell-based assays. Standard cell culture protocols for test compounds synthesized from this intermediate involve dissolving the final product in DMSO and diluting to working concentrations in appropriate cell culture medium.
|
| Animal Protocol |
In vivo animal studies using pyridazine are conducted on the final drug compounds synthesized from it, not on the intermediate itself. For pharmaceuticals derived from the pyridazine scaffold, such as olaparib and talazoparib, efficacy studies would typically be performed in mouse models of the relevant disease. Standard in vivo protocols involve administration to rodents via oral gavage or intraperitoneal injection.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of pyridazine as a standalone compound are not characterized in the literature. The compound has a molecular weight of 80.09 g/mol, which is very favorable for oral bioavailability. The density is 1.103 g/mL and the boiling point is 208°C. Empirical pharmacokinetic data are not available for this intermediate compound.
|
| Toxicity/Toxicokinetics |
Pyridazine is a research chemical and should be handled with appropriate laboratory safety precautions. As a liquid with a flash point of 85°C, it should be stored away from heat and open flames. It may pose risks of skin and eye irritation. Specific LD₅₀ values, acute toxicity classifications, and chronic toxicity data are not available in the public literature. Standard safety practices include the use of personal protective equipment and working in a fume hood.
|
| Additional Infomation |
Pyridazine is a type of pyridazine and diazine compound.
Pyridazine (CAS 289-80-5) is primarily a research-grade chemical intermediate, not an FDA-approved pharmaceutical drug. Its primary applications are as a building block for more complex compounds in research and industry. The pyridazine ring is found in many herbicides like credazine and pyridatol, and in many pharmaceutical drugs like cefozopran, olaparib, and talazoparib. No clinical trials or approved indications exist for this compound as a drug substance. |
| Molecular Formula |
C4H4N2
|
|---|---|
| Molecular Weight |
80.09
|
| Exact Mass |
80.037
|
| CAS # |
289-80-5
|
| Related CAS # |
95109-07-2
|
| PubChem CID |
9259
|
| Appearance |
Liquid（Density：1.103 g/cm3）
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
208.0±0.0 °C at 760 mmHg
|
| Melting Point |
−8 °C(lit.)
|
| Flash Point |
85.0±0.0 °C
|
| Vapour Pressure |
0.3±0.3 mmHg at 25°C
|
| Index of Refraction |
1.503
|
| LogP |
-0.77
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
6
|
| Complexity |
30.5
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N1=C([H])C([H])=C([H])C([H])=N1
|
| InChi Key |
PBMFSQRYOILNGV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C4H4N2/c1-2-4-6-5-3-1/h1-4H
|
| Chemical Name |
pyridazine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 12.4860 mL | 62.4298 mL | 124.8595 mL | |
| 5 mM | 2.4972 mL | 12.4860 mL | 24.9719 mL | |
| 10 mM | 1.2486 mL | 6.2430 mL | 12.4860 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
